We are live on ! Find out more

Diagnostics & Research
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
TMO icon
1
Thermo Fisher Scientific
TMO
$225B
$225B $609.82 1.1%
DHR icon
2
Danaher
DHR
$141B
$141B $200.14 0.19%
NTRA icon
3
Natera
NTRA
$47.4B
$47.4B $328.93 0.86%
IQV icon
4
IQVIA
IQV
$43.1B
$43.1B $261.77 1.74%
A icon
5
Agilent Technologies
A
$41.4B
$41.4B $146.93 2.66%
WAT icon
6
Waters Corp
WAT
$40.1B
$40.1B $408.34 1.67%
IDXX icon
7
Idexx Laboratories
IDXX
$39.8B
$39.8B $504.70 0.36%
ILMN icon
8
Illumina
ILMN
$31.2B
$31.2B $206.45 2.57%
DGX icon
9
Quest Diagnostics
DGX
$25.9B
$25.9B $235.02 1.68%
MTD icon
10
Mettler-Toledo International
MTD
$25.9B
$25.9B $1,293.52 1.01%
LH icon
11
Labcorp
LH
$25.3B
$25.3B $311.54 1.49%
GH icon
12
Guardant Health
GH
$21.1B
$21.1B $157.38 1.04%
MEDP icon
13
Medpace
MEDP
$16.4B
$16.4B $587.52 0.75%
RVTY icon
14
Revvity
RVTY
$13.9B
$13.9B $124.31 2.79%
CRL icon
15
Charles River Laboratories
CRL
$13.3B
$13.3B $278.26 1.93%
ICLR icon
16
Icon
ICLR
$13.1B
$13.1B $169.31 2.18%
QGEN icon
17
Qiagen
QGEN
$8.78B
$8.78B $42.50 0.88%
RDNT icon
18
RadNet
RDNT
$5.94B
$5.94B $75.49 1.63%
SHC icon
19
Sotera Health
SHC
$5.24B
$5.24B $18.37 0.6%
BLLN
20
BillionToOne Inc
BLLN
$4.66B
$4.66B $98.77 0.26%
ADPT icon
21
Adaptive Biotechnologies
ADPT
$3.86B
$3.86B $24.20 0.12%
GRAL
22
GRAIL Inc
GRAL
$3.4B
$3.4B $76.23 1.71%
VCYT icon
23
Veracyte
VCYT
$3.29B
$3.29B $40.87 2.76%
CDNA icon
24
CareDx
CDNA
$2.6B
$2.6B $50.26 0.48%
WGS icon
25
GeneDx Holdings
WGS
$2.54B
$2.54B $85.27 1.56%
1
2

Diagnostics & Research Stocks at a Glance

Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.

There are 46 Diagnostics & Research industry stocks tracked by Wall St. Rank, worth a combined $814B.

The largest by market cap are Thermo Fisher Scientific (TMO) at $225B, Danaher (DHR) at $141B and Natera (NTRA) at $47.4B.

Among institutional investors, Guardant Health (GH) drew the most net new fund positions in Q2 2026: 158 funds opened new positions, taking total fund holders up 112 (23%) quarter-over-quarter.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.